Edition:
United Kingdom

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

153.64USD
19 Sep 2018
Change (% chg)

$4.44 (+2.98%)
Prev Close
$149.20
Open
$154.00
Day's High
$166.18
Day's Low
$150.27
Volume
607,611
Avg. Vol
96,495
52-wk High
$166.18
52-wk Low
$96.43

Latest Key Developments (Source: Significant Developments)

GW Pharmaceuticals Reports Fiscal Q3 Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC REPORTS FISCAL THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.  Full Article

FDA Approves Epidiolex (Cannabidiol) Oral Solution To Treat Rare, Severe Forms Of Epilepsy
Monday, 25 Jun 2018 

June 25 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION FOR TREATMENT OF SEIZURES ASSOCIATED WITH 2 SEVERE FORMS OF EPILEPSY IN PATIENTS 2 YRS & OLDER.U.S. FDA - FDA GRANTED APPROVAL OF EPIDIOLEX TO GW RESEARCH LTD.U.S. FDA - EPIDIOLEX APPROVED FOR TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME & DRAVET SYNDROME IN PATIENTS 2 YRS & OLDER.  Full Article

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - GW Pharmaceuticals Plc ::GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S..GW PHARMACEUTICALS - NOW REACQUIRED FULL OWNERSHIP OF DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT IN U.S. WITHOUT UPFRONT PAYMENT TO OTSUKA​.GW PHARMACEUTICALS - ‍AGREED TO MAKE CONTINGENT MILESTONE PAYMENTS TO OTSUKA, FIRST OF WHICH WOULD BECOME DUE UPON FDA APPROVAL OF SATIVEX​.GW PHARMACEUTICALS PLC - ‍TERMINATION OF PREVIOUS LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO IN RELATION TO SATIVEX IN U.S.​.  Full Article

GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Gw Pharmaceuticals Plc ::GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.GW PHARMACEUTICALS PLC - INTENDS TO SELL $225 MILLION OF AMERICAN DEPOSITARY SHARES.  Full Article

Photo

Scientists unpick how cannabis component may fight psychosis

LONDON British scientists have unraveled how a non-intoxicating component of cannabis acts in key brain areas to reduce abnormal activity in patients at risk of psychosis, suggesting the ingredient could become a novel anti-psychotic medicine.